"There couldn't be a more pressing or galvanizing topic for Americans than the high cost of prescription drugs. And after months of blustery talk from President Donald Trump about lowering prices and cracking down on Big Pharma, his plans are finally starting to take shape, beginning with pacts with manufacturers. But before we get too excited, consumers should demand more transparency about what they're getting from his dealmaking and ask who is truly benefiting from the sum of his health care actions."
"Trump wisely put the issue of drug costs front and center, promising consumers a better deal than what his predecessors could extract from companies. His main strategy has been to threaten pharma companies with outlandishly high tariffs if they didn't comply with his demands, which included reshoring manufacturing, bringing U.S. drug prices in line with those in Europe, and expanding direct-to-consumer sales."
High prescription drug costs are a pressing issue for Americans. President Donald Trump's plans to lower prices are taking shape through pacts with manufacturers. His approach has centered on threatening extreme tariffs to push reshoring, price alignment with Europe, and expanded direct-to-consumer sales. The Pfizer agreement reportedly offers most-favored-nation prices to Medicaid, commitments to invest in U.S. production, and placement of branded drugs on a TrumpRx portal in exchange for a three-year tariff exemption. Other companies appear to be negotiating deals. Careful, voluntary, and confidential language in the agreements suggests limited transparency and potential PR gains for manufacturers.
Read at www.mercurynews.com
Unable to calculate read time
Collection
[
|
...
]